ObjectiveThere are currently 11 antibody-drug conjugates (ADC) that are FDA approved for use in oncologic disease states, with many more in the pipeline. The authors aim to review the pharmacokinetic profiles of the components of ADCs to engage pharmacist practitioners in practical considerations in the care of patients. This article provides an overview on the use of ADCs in the setting of organ dysfunction, drug–drug interactions, and management of on- and off-target adverse effects.Data SourcesA systematic search of the literature on ADCs through September 2023 was conducted. Clinical trials as well as articles on ADC design and functional components, adverse effects, and pharmacokinetics were reviewed. Reviewed literature included prescribing information as well as tertiary sources and primary literature.Data SummaryA total of 11 ADCs were reviewed for the purpose of this article. A description of the mechanism of action and structure of ADCs is outlined, and a table containing description of each currently FDA-approved ADC is included. Various mechanisms of ADC toxicity are reviewed, including how ADC structure may be implicated.ConclusionIt is imperative that pharmacist clinicians understand the design and function of each component of an ADC to continue to assess new approvals for use in oncology patients. Understanding the design of the ADC can help a pharmacy practitioner compare and contrast adverse effect profiles to support their multidisciplinary teams and to engage patients in education and management of their care.

中文翻译：

---

抗体药物偶联物：设计对临床医生的影响

目的 目前有 11 种抗体药物偶联物 (ADC) 经 FDA 批准用于肿瘤疾病状态，还有更多正在研发中。作者旨在回顾 ADC 成分的药代动力学特征，以使药剂师在患者护理中实际考虑。本文概述了 ADC 在器官功能障碍、药物间相互作用以及靶标和脱靶不良反应管理中的使用。数据来源对截至 2023 年 9 月有关 ADC 的文献进行了系统检索。回顾了临床试验以及有关 ADC 设计和功能成分、不良反应和药代动力学的文章。审阅的文献包括处方信息以及第三来源和主要文献。数据摘要出于本文的目的，总共审阅了 11 种 ADC。概述了 ADC 的作用机制和结构，并包含一个表格，其中包含当前 FDA 批准的每种 ADC 的描述。回顾了 ADC 毒性的各种机制，包括 ADC 结构可能如何涉及。结论药剂师临床医生必须了解 ADC 每个组件的设计和功能，以继续评估用于肿瘤患者的新批准。了解 ADC 的设计可以帮助药房从业者比较和对比不良反应概况，以支持他们的多学科团队并让患者参与其护理的教育和管理。